Kybernin P

Antithrombin III, the active ingredient in Kybernin P, is an antithrombin concentrate presented as an injectable solution for intravenous use. It is employed to prevent and treat bleeding in patients with antithrombin deficiency and to manage heparin resistance.

GNH USA supplies Kybernin P as a licensed, GDP‑compliant international pharmaceutical supplier serving hospitals, transplant centres and specialty clinics worldwide. The company adheres to stringent quality standards and provides cold‑chain logistics to ensure product integrity during global distribution through to clients.

Kybernin P is an antithrombin concentrate used to address disorders of the coagulation cascade. - Antithrombin deficiency: restores deficient antithrombin activity, thereby preventing spontaneous or procedure‑related bleeding and supporting hemostasis in affected patients. - Heparin resistance: supplies functional antithrombin to augment heparin’s anticoagulant effect, enabling adequate anticoagulation in individuals who exhibit inadequate response to standard heparin therapy.

Antithrombin III concentrates may be associated with several adverse reactions, ranging from mild infusion‑related events to rare but serious complications. Common Side Effects: - Infusion site erythema or pain - Fever or chills - Headache - Nausea - Mild transient hypotension - Slight elevation of liver enzymes Serious or Rare Side Effects: - Anaphylactic reaction - Severe hypotension or shock - Thrombotic events - Hemolysis - Serum sickness - Disseminated intravascular coagulation (rare)

When using Kybernin P, clinicians should observe specific precautions to ensure safety and therapeutic effectiveness. - Antithrombin level monitoring: measure plasma antithrombin activity before and during therapy to avoid over‑correction. - Bleeding risk assessment: evaluate patient’s bleeding history and concomitant anticoagulant use. - Hypersensitivity screening: avoid in patients with known allergy to antithrombin concentrates or excipients. - Renal or hepatic impairment: adjust dosing and monitor closely in patients with organ dysfunction. - Pregnancy and lactation: use only if potential benefit justifies potential risk; data are limited. - Store at 2-8°C: keep refrigerated, protect from light, do not freeze or shake.

Antithrombin III may interact with other agents that affect coagulation, requiring careful management. Major Interactions (Avoid): - Concurrent high‑dose heparin: may cause excessive anticoagulation and bleeding. - Direct thrombin inhibitors (e.g., dabigatran): additive anticoagulant effect increasing hemorrhage risk. - Other antithrombin products: risk of over‑replacement and thrombosis. Moderate Interactions (Monitor Closely): - Warfarin or vitamin K antagonists: monitor INR as antithrombin can potentiate anticoagulant effect. - Antiplatelet agents (aspirin, clopidogrel): increased bleeding tendency. - Non‑steroidal anti‑inflammatory drugs (NSAIDs): may exacerbate gastrointestinal bleeding. - Immunosuppressants (e.g., rituximab): possible altered immune response to protein product.